Genetic events and the role of TGFβ in epithelial tumour progression

Journal of Pathology

Volumn 187, Issue 1, 1999, Pages 82-90

  Akhurst, Rosemary J ^b   Balmain, Allan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ONYX PHARMACEUTICALS   (United States)

Author keywords

Chemical carcinogenesis; H ras; INK4; Keratinocyte; p53; Skin; SMADs; TGF ; Tumour invasion and metastasis

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA;

ALLELE; ANIMAL TISSUE; CANCER INVASION; CARCINOGENESIS; CELL TRANSFORMATION; EPITHELIUM TUMOR; GENE DELETION; GENE LOCUS; GENE OVEREXPRESSION; KERATINOCYTE; KNOCKOUT MOUSE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; REVIEW; TRANSGENIC MOUSE;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; EPITHELIUM; GENES, P53; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; SKIN NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032909086     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8     Document Type: Review

References (138)

1. Rochat A, Konayashi K, Barrandon Y. Location of stem cells of human hair follicles by clonal analysis. Cell 1994; 76: 1063-1073.
2. Potten CS, Potten CS, eds. Stem cells in epidermis from the back of the mouse. In: Stem Cells: Their Identification and Characterisation. Edinburgh: Churchill Livingstone, 1983; 203-232.
3. Cotsarelis G, Sun T-T, Lavker RM. Label-retaining cells reside in the bulge area of pilosebaceous unit: implications for follicular stem cells, hair cycle, and skin carcinogenesis. Cell 1990; 61: 1329-1337.
4. Potten CS, Loeffler M. Stem cells: attributes, cycles, spirals, pitfalls and uncertainties: lessons from the crypt. Development 1990; 110: 1001-1020.
5. Cotsarelis G, Cheng S-Z, Dong G, Sun T-TLRM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells. Cell 1989; 57: 21.
6. Hunter T. Co-operation between oncogenes. Cell 1991; 64: 249-270.
7. Weinberg RA. Oncogenes, anti-oncogenes and the molecular bases of multistep carcinogenesis. Cancer Res 1989; 49: 3713-3721.
8. Balmain A, Kemp CJ, Burns PA, Stoler AB, Fowlis DJ, Akhurst RJ. Functional loss of tumour suppressor genes in multi-stage chemical carcinogenesis. Princess Takematsu Symp 1991; 22: 97-108.
9. Rosenthal FM. Human tumor vaccines and genetic engineering of tumors with cytokine and histocompalibility genes to enhance immunogenicity. Curr Opin Oncol 1994; 6: 611-615.
10. Hennings H, Spangler EF, Shores R, et al. Induction of papillomas with a high probability of conversion to malignancy. Carcinogenesis 1985; 6: 1607-1610.
11. Klein-Szanto AJ, Larcher F, Bonfil RD, Conn CJ. Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin. Carcinogenesis 1989; 10: 2169-2172.
12. Stoler A, Stenback F, Balmain A. The conversion of mouse skin squamous cell carcinomas to spindle cell carcinomas is a recessive event. J Cell Biol 1993; 122: 1103-1117.
13. Cano A, Gamalla C, Kemp CJ, et al. The expression of the cell adhesion molecules E-cadherin, P-cadherin and α6β4 integrin is altered in premalignant skin tumours of p53-deficient mice. Int J Cancer 1996; 65: 254-262.
14. Navarro P, Gomez M, Pizarro A, Gamallo C, Quintanilla M, Cano A. A role for the E-cadherin cell cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. J Cell Biol 1991; 115: 517-533.
15. Bizub D, Wood AW, Skalka AM. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci USA 1986; 83: 6048-6051.
16. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature (London) 1986; 322: 78-80.
17. Zarbl H, Sukumar S, Arthur AV, Martin-Zanca D, Barbacid M. Direct mutagenests of Ha-ras-1 oncogenes by N-nitroso-N-methylurea during initiation of mammary carcinogenesis in rats. Nature 1985; 315: 382-385.
18. Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA 1990; 87: 538-542.
19. Roop DR, Lowy DR, Tambourin PE, et al. An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. Nature 1986; 323: 822-824.
20. Brown K, Quintanilla M, Ramsden M, Kerr IB, Young S, Balmain A. v-ras genes from Harvey and BALB murine sarcoma viruses can act as initiators of two-stage mouse skin carcinogenesis. Cell 1986; 46: 447-456.
21. Quintanilla M, Haddow S, Jonas D, Jaffe D, Bowden GT, Balmain A. Comparison of ras activation during epidermal carcinogenesis in vitro and in vivo. Carcinogenesis 1991; 12: 1875-1881.
22. Bremner R, Balmain A. Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. Cell 1990; 61: 407-417.
23. Bremner R, Kemp CJ, Balmain A. Induction of different genetic changes by different classes ol chemical carcinogens during progression of mouse skin tumors. Mol Carcinog 1994; 11: 90-97.
24. Bianchi AB, Aldaz CM, Conti CJ. Nonrandom duplication of the chromosome bearing it mutated Ha-ras-1 allele in mouse skin tumors. Proc Nall Acad Sci USA 1990; 87: 6902-6906.
25. Crombie R. Multiple thresholds of Ras activity during the conversion of squamous to spindle cell carcinomas. PhD Thesis dissertation. Glasgow University, 1996.
26. Green JBA, Smith JC. Graded changes in dose of a Xenopus activin A homologue elicit stepwise transitions in embryonic cell fate. Nature 1990; 347: 391-394.
27. Whitman M, Melton DA. Involvement of p21ras in Xenopus mesoderm induction. Nature 1992; 357: 252-254.
28. de Vries-Smits AM, Burgering BM, Leevers SJ, Marshall CJ, Bos JL. Involvement of p21ras in activation of extracellular signal-regulated kinase 2. Nature 1992; 357: 602-604.
29. Marshall CJ. MAP kinase kinase kinase. MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994; 4: 82-89.
30. Marshall CJ. Ras effectors. Curr Opin Cell Biol 1996; 8: 197-204.
31. Webb CP, Van Aelst L, Wigler MH, Vande Woude GK. Signaling pathways in ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 1998; 95: 8773-8778.
32. Bailleul B, Surani MA, White S, et al. Skin hyperkeratosis and papilloma formation in transgenic mice expressing a ras oncogene from a saprabasal keratin promotor. Cell 1990; 62: 697-708.
33. Greenhalgh DA, Rothnagel JA, Quintanilla MI, et al. Induction of epidermal hyperplasia, hyperkeratosis, and papillomas in transgenic mice by a targeted v-Ha-ras oncogene. Mol Carcinog 1993; 7: 99-110.
34. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p161NK4a. Cell 1997; 88: 593-602.
35. Greenhalgh DA, Quintanilla MI, Orengo CC, et al. Cooperation between v-fos and v-rasHA induces autonomous papillomas in transgenic epidermis but not malignant conversion. Cancer Res 1993; 53: 5071-5075.
36. Brown K, Strathdee D, Bryson S, Lambie W, Balmain A. The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. Curr Biol 1998; 8: 516-524.
37. Burns PA, Kemp CJ, Gannon JV, Lane DP, Bremner R, Balmain A. Loss of heterozygosity and mutational alterations of the p53 gene in skin tumors of interspecific hybrid mice. Oncogene 1991; 6: 2363-2369.
38. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, Klein-Szanto AJ. Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci USA 1993; 90: 1013-1017.
39. Kemp CJ, Burns PA, Brown K, Nagase H, Balmain A. Transgenic approaches to the analysis of ras and p53 function in multistage carcinogenesis. Cold Spring Harbor Symp Quant Biol 1994; 59: 427-434.
40. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90: 4216-4220.
41. Nataraj AJ, Black HS, Ananthaswamy HN. Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci USA 1996; 93: 7961-7965.
42. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 1993; 74: 813-822.
43. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res 1996; 56: 4413-4423
44. MacCallum DE, Hupp TR, Midgley CA, et al. The p53 response to ionising radiation in adult and developing murine tissues. Oncogene 1996; 13: 2575-2587.
45. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nature Med 1998; 4: 839-843.
46. Frixen UH, Behrens J, Sachs M, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991; 113: 173-185.
47. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-111.
48. Bajou K, Noel A, Gerard RD, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nature Med 1998; 4: 923-928.
49. Evans HL, Baer SC. Epithelioid sarcoma: a clinicopathologic and prognostic study of 26 cases. Semin Diagn Pathol 1993; 10: 286-291.
50. Evans HL, Smith JL. Spindle cell squamous carcinomas and sarcoma-like tumors of the skin: a comparative study of 38 cases. Cancer 1980; 45: 2687-2697.
51. Battifora H. Spindle cell carcinoma: ultrastructural evidence of squamous origin and collagen production by the tumor cells. Cancer 1976; 37: 2275-2282.
52. Vande Woude G, Jeffers M, Cortner J, Alvord G, Tsarfaty I, Resau J. Met-HGF/SF: tumorigenesis, invasion and metastasis. Ciba Found Symp 1997; 212: 119-130.
53. Becker KF, Atkinson MJ, Reich U, Huang HH, Siewart JR, Hofler H. Exon skipping in the E-cadherin gene transcript in metastatic human gastric carcinomas. Hum Mol Genet 1993; 2: 803-804.
54. Becker KF, Atkinson MJ, Reich U, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994; 54: 3845-3852.
55. Oda T, Kanai Y, Oyama T, et al. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 1994; 91: 1858-1862.
56. Risinger J, Berchuck A, Kohler M, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nature Genet 1994; 7: 98-102.
57. Behrens J, Vakaet L, Friis R, et al. Loss of epithelial differentiation and gain of invasiveness correlate with tyrosine phosphorylation of the E-cadherin/β-catenin complex in cells transformed with a temperature-sensitive v-SRC gene. J Cell Biol 1993; 120: 757-766.
58. Hamaguchi M, Matsuyoshi N, Ohnishi Y, Goloh B, Takeichi M, Nagai Y. p60 causes tyrosine phosphorylation and inactivation of the N-cadherin catenin cell adhesion system. EMBO J 1993; 12: 307-314.
59. Hirst RA, Horwitz A, Buck C, Rohrschneider L. Phosphorylation of the fibronectin receptor complex in cells transformed by oncogenes that encode tyrosine kinases. Proc Natl Acad Sci USA 1986; 83: 6470-6474.
60. Emardopoulos S, Street AJ, Quelle DE, et al. Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res 1995; 55: 5168-5172.
61. Buchmann A, Ruggeri B, Klein-Szanto AJP, Balmain A. Progression of squamous carcinoma cells to spindle carcinoma of the mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. Cancer Res 1991; 51: 4097-4101.
62. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257-261.
63. Liddell J. Genetic and biochemical factors involved in progression of mouse skin tumours. PhD Thesis dissertation. Glasgow University, 1995.
64. Portella G, Cumming SA, Liddell J, et al. Transforming growth factor beta is essential for spindle cell conversion of mouse skin carcinoma in vivo: implications for tumor invasion. Cell Growth Differ 1998; 9: 393-404.
65. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-β1 and Ha-ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996; 10: 2462-2477.
66. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994; 127: 2021-2036.
67. Caulin C, Scholl SG, Frontelo P, GamalloC, Quintanilla M. Chronic exposure of cultured transfected mouse epidermal cells to TGFβ1 induces an epithelial mesenchymal transdiffcrentiation and a spindle tumoral phenotype. Cell Growth Differ 1995; 6: 1027-1035.
68. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-beta cDNA sequence and expression in tumor cell lines. Nature 1985; 316: 701-705.
69. Glynne-Jones E, Harper ME, Goddard L, Eaton CL, Matthews PN, Griffiths K. Transforming growth factor beta 1 expression in benign and malignant prostatic tumors. Prastate 1994; 25: 210-218.
70. Donnelly MJ, Patel V, Yeudall WA, Game SM, Scully C, Prime SS. Autocrine production of TGF-alpha and TGF-beta during tumour progression of rat oral keratinocytes. Carcinogenesis 1993; 14: 981-985.
71. Krieg P, Schnapke R, Furstenberger G, Vogt I, Marks F. TGF-beta 1 and skin carcinogenesis: antiproliferative effect in vitro and TGF-beta 1 mRNA expression during epidermal hyperproliferation and multistage tumorigenesis. Mol Carcinog 1991; 4: 129-137.
72. Arrick BA, Lopez AR, Elfman F, Ebner R, Damsky CH, Derynck R. Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor βl. J Cell Biol 1992; 118: 715-726.
73. Sieweke MH, Bissell MJ. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations. Crit Rev Oncog 1994; 5: 297-311.
74. Guise TA, Mundy GR. Cancer and bone. Endocr Rer 1998; 19: 18-54.
75. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83: 4167-4171.
76. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acal Sci USA 1990; 87: 7678-7682.
77. Arteaga C, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT. Anti-transforming growth factor (TGF)-β antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer activity. J Clin Invest 1993; 92: 2569-2576.
78. De Larco JE, Todaro GJ. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci USA 1978; 75: 4001-4005.
79. Roberts AB, Anzano MA, Lamb LC, et al. Isolation from murine sarcoma cells of novel transforming growth factors potentiated by EGF. Nature 1982; 295: 417-419.
80. Akhurst RJ, Fee F, Balmain A. Localized production of TGF-beta mRNA in tumour promoter-stimulated mouse epidermis. Nature 1988; 331: 363-365.
81. Cui W, Fowlis DJ, Cousins FM, et al. Concerted action of TGFβ1 and its type II receptor in control of epidermal homeostasis in transgenic mice. Genes Dev 1995; 9: 945-955
82. Reynisdottir I, Polyak K, Iavarone A, Massagué J. Kip/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev 1995; 9: 1831-1845.
83. Reynisdottir I, Massague J. The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Der 1997; 11: 492-503.
84. Ewen ME. p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest. J Lab Clin Med 1996; 128: 355-360.
85. Ewen ME, Oliver CJ, Sluss HK, Miller SJ, Peeper DS. p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev 1995; 9: 204-217.
86. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM. TGF beta inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 1993; 74: 1009-1020.
87. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331-342.
88. Iavarone A, Massague J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15. Nature 1997; 387: 417-422.
89. Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature 1997; 390: 465-471.
90. Padgett RW, Das P, Krishna S. TGF-beta signaling, Smads, and tumor suppressors. BioEssays 1998; 20: 382-390.
91. Kretzschmar M, Massague J. SMADs: mediators and regulators of TGF-beta signaling. Curr Opin Genet Dev 1998; 8: 103-111.
92. Zhou S, Zawel L, Lengauer C, Kinzler KW, Vogelstein B. Characterization of human FAST-1, a TGF beta and activin signal transducer. Mol Cell 1998; 2: 121-127.
93. Labbe E, Silvestri C, Hoodless PA, Wrana JL, Attisano L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol Cell 1998; 2: 109-120.
94. Lu SL, Akiyama Y, Nagasaki H, Saitoh K, Yuasa Y. Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun 1995; 216: 452-457.
95. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-1338.
96. Shitara Y, Yokozaki H, Yasui W, Takenoshita S, Nagamachi Y, Tahara E. Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas. Int J Oncol 1998; 12: 1061-1065.
97. Eppert K, Scherer SW, Ozcelik H, et al. MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86: 543-552.
98. Hahn SA, Schutte M, Shamsul Hoque ATM, et al. DPC4, a candidate tumour suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-353.
99. Riggins GJ. Frequency of Smad gene mutations in human cancers. Cancer Res 1997; 57: 2578-2580.
100. Schutte M. DPC4 gene in various tumor types. Cancer Res 1996; 56: 2527-2530.
101. Arai T, Akiyama Y, Okabe S, Ando M, Endo M, Yuasa Y. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers. Cancer Lett 1998; 122: 157-163.
102. Gemma A, Hagiwara K, Vincent F, et al. hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors. Oncogene 1998; 16: 951-956.
103. Takaku K, Oshima M, Miyoshi H, Matsui M, Seldin MF, Taketo MM. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998; 92: 645-656.
104. Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280: 1086-1088.
105. Amendt C, Schirmacher P, Weber H, Blessing M. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 1998; 17: 25-34.
106. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997; 57: 5564-5570.
107. Cui W, Fowlis DJ, Bryson S. et al. TGFβ1 inhibits the formation of benign skin tumours but enhances progression to invasive spindle cell carcinomas in transgenic mice. Cell 1996; 86: 531-542.
108. Tang B, Bottinger EP, Jakowlew SB, et al. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nature Med 1998; 4: 802-807.
109. Fowlis DJ, Cui W, Johnson SA, Balmain A, Akhurst RJ. Altered epidermal growth control in vivo in transgenic mice expressing TGFbeta1 from an inducible keratin gene promoter. Cell Growth Diff 1996; 7: 679-687.
110. Wang XJ, Greenhalgh DA, Bickenbach JR, et al. Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci USA 1997; 94: 2386-2391.
111. Zhu Y, Richardson JA, Parada LF, Fraff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998; 94: 1-20.
112. Glick AB, Kulkarni AB, Tennenbaum T, et al. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993; 90: 6076-6080.
113. Haddow S, Fowlis DJ, Parkinson K, Akhurst RJ, Balmain A. Loss of growth control by TGFβ occurs at a late stage of mouse carcinogenesis and is independent of ras gene activation. Oncogene 1991; 6: 1465-1470.
114. Baldwin RL, Korc M. Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. Growth Factors 1993; 8: 23-34.
115. Hebert CD, Birnbaum LS. Lack of correlation between sensitivity to growth inhibition and receptor number of transforming growth factor beta in human squamous carcinoma cell lines. Cancer Res 1989; 49: 3196-3202.
116. Khosla S, Oursler MJ, Schroeder MJ, Eberhardt NL. Transforming growth factor-beta 1 induces growth inhibition of a human medullary thyroid carcinoma cell line despite an increase in steady state c-myc messenger ribonucleic acid levels. Endocrinology 1994; 135: 1887-1893.
117. Malliri A, Yeudall WA, Nikolic M, Crouch DH, Parkinson EK, Ozanne B. Sensitivity to transforming growth factor beta 1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21wafl induction are important early events. Cell Growth Differ 1996; 7: 1291-1304.
118. Paterson IC, Patel V, Sandy JR, Prime SS, Yeudall WA. Effects of transforming growth factor beta-1 on growth-regulatory genes in tumour-derived human oral keratinocytes. Br J Cancer 1995; 72: 922-927.
119. Mazars P, Barboule N, Baldin V, Vidal S, Ducommun B, Valette A. Effects of TGF-beta 1 (transforming growth factor-beta 1) on the cell cycle regulation of human breast adenocarcinoma (MCF-7) cells. FEBS Lett 1995; 362: 295-300.
120. Geiser AG, Burmester JK, Webbink R, Roberts AB, Sporn MB. Inhibition of growth by transforming growth factor-β following fusion of two non-responsive human carcinoma cell lines. J Biol Chem 1992; 267: 2588-2593.
121. Centrella M, Casinghino S, Kim J, et al. Independent changes in type 1 and type II receptors for transforming growth factor β induced by bone morphogenetic protein 2 parallel expression of the osteoblast phenotype. Mol Cell Biol 1995; 15: 3273-3281.
122. Dyson S, Gurdon JB. The interpretation of position in a morphogen gradient as revealed by occupancy of activin receptors. Cell 1998; 93: 557-568.
123. Bubb VJ, Curtis LJ, Cunningham C, et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 1996; 12: 2641-2649.
124. de Caestecker MP, Parks WT, Frank CJ, et al. Smad2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 1998; 12: 1587-1592.
125. Mulder KM, Morris SL. Activation of p21-ras by transforming growth factor beta in epithelial cells. J Biol Chem 1992; 267: 5029-5011.
126. Hartsough MT, Frey RS, Zipfel PA, et al. Altered transforming growth factor signaling in epithelial cells when ras activation is blocked. J Biol Chem 1996; 271: 22368-22375.
127. Yue J, Buard A, Mulder KM. Blockade of TGFbeta3 up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells. Oncogene 1998; 17: 47-55.
128. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995; 270: 2008-2011.
129. Shibuya H, Yamaguchi K, Shirakabe K, et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 1996; 272: 1179-1182.
130. Kondo M, Osada H, Uchida K, et al. Molecular cloning of human TAK1 and its mutational analysis in human lung cancer. Int J Cancer 1998; 75: 559-563.
131. Zhang Y, Feng XH, Derynck R. Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription. Nature 1998; 394: 909-913.
132. Lamb RF, Hennigan RF, Turnbull K, et al. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol Cell Biol 1997; 17: 963-976.
133. Denhardt DT. Oncogene-initiated aberrant signaling engenders the metastatic phenotype: synergistic transcription factor interactions are targets for cancer therapy. Crit Rev Oncog 1996; 7: 261-291.
134. Zhou JN, Ljungdahl S, Shoshan MC, Swedenborg J, Linder S. Activation of tissue-factor gene expression in breast carcinoma cells by stimulation of the RAF-ERK signaling pathway. Mol Carcinog 1998; 21: 234-243.
135. Feng XH, Zhang Y, Wu RY, Derynck R. The tumor suppressor Smad4/DPC4 and transcnptional adaptor CBP/p300 are coactivators for Smad3 in TGF-beta-induced transcriptional activation. Genes Dev 1998; 12: 2153-2163.
136. Pouponnot C, Jayaraman L, Massague J. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem 1998; 273: 22865-22868.
137. Janknecht R, Wells NJ, Hunter T. TGF-beta-stimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Der 1998; 12: 2114-2119.
138. Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996; 85: 403-414.